AstraZeneca Pfizer raises cash component for AstraZeneca bid to £55/shr; Cash component increased to 45% from 33%; Proposal said to be final
- AZN shareholders would receive 1.747 shares in compbined equity and £24.76 in cash.
- Does not intend to proceed with a hostile bid if the latest offer is rejected by the Board.